Search results for "SILDENAFIL"

showing 10 items of 38 documents

Sildenafil reduces neuroinflammation and restores spatial learning in rats with hepatic encephalopathy: underlying mechanisms

2015

Background: There are no specific treatments for the neurological alterations of cirrhotic patients with minimal hepatic encephalopathy (MHE). Rats with MHE due to portacaval shunt (PCS) show impaired spatial learning. The underlying mechanisms remain unknown. The aims of this work were to assess: (a) whether PCS rats show neuroinflammation in hippocampus, (b) whether treatment with sildenafil reduces neuroinflammation and restores spatial learning in PCS rats, and (c) analyze the underlying mechanisms. Methods: Neuroinflammation was assessed by determining inflammatory markers by Western blot. Phosphorylation of MAP-kinase p38 was assessed by immunohistochemistry. Membrane expression of GA…

Malemedicine.medical_specialtyNeurologySildenafilVasodilator AgentsInterleukin-1betaImmunologyHippocampusInflammationPortacaval shuntHippocampusp38 Mitogen-Activated Protein KinasesSildenafil Citratechemistry.chemical_compoundCellular and Molecular NeuroscienceReceptors GABANeuroinflammationmedicineAnimalsRats WistarMaze LearningHepatic encephalopathyNeuroinflammationHepatic encephalopathyInflammationMicrogliaPortacaval Shunt SurgicalTumor Necrosis Factor-alphabusiness.industryResearchGeneral NeuroscienceMacrophage Activationmedicine.diseasehumanitiesSildenafil treatmentRatscGMPmedicine.anatomical_structureCognitive impairmentReceptors Glutamatechemistrynervous systemNeurologyHepatic EncephalopathyMicrogliamedicine.symptombusinesshuman activitiesNeuroscience
researchProduct

Sildenafil orodispersible film in the treatment of erectile dysfunction after radical prostatectomy: A single‐centre open‐label uncontrolled trial

2020

Phosphodiesterase-5 inhibitors are the first-line therapy for erectile dysfunction (ED) after radical prostatectomy (RP). This single-centre open-label uncontrolled study evaluated the efficacy and safety of the new sildenafil orodispersible film (ODF) in ED treatment after RP. Sildenafil 100 mg ODF was administered twice a week for 3 months to patients under 75 years of age, with a Framingham cardiovascular risk score < 20% and a pre-operative International Index of Erectile Function (IIEF)-5 score ≥ 17, who had undergone open RP between 2016 and 2018. Erectile function was assessed pre-operatively, post-operatively and after treatment through the IIEF-5 score, the Sexual Encounter Prof…

Malemedicine.medical_specialtyPercentileSildenafilUrologymedicine.medical_treatment030232 urology & nephrologyUrologyUncontrolled Studyprostatic neoplasmsSildenafil Citrate03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyErectile DysfunctiontherapeuticsHumansMedicineAdverse effectProstatectomy030219 obstetrics & reproductive medicineFramingham Risk Scorebusiness.industryProstatectomyPenile ErectionOrodispersible filmGeneral MedicinePhosphodiesterase 5 Inhibitorsmedicine.diseaseTreatment OutcomeErectile dysfunctionchemistrybusinessAndrologia
researchProduct

Lower self-reported depression in patients with erectile dysfunction after treatment with sildenafil

2001

Abstract Background: Depressive symptoms in men with erectile dysfunction (ED) may improve under successful ED treatment. Self-reported depressive symptoms were compared in men with ED after sildenafil treatment to a group of untreated patients. Methods: In an open study, self-reported depressive symptoms of 54 men after successful treatment with sildenafil (>4 weeks) and 51 men awaiting ED treatment were investigated with the Center of Epidemiologic Studies–Depression Scale (CES–D). CES–D items were subjected to an exploratory factor analysis and group differences in CES–D items and factors were analyzed. Results: Groups were comparable with respect to demographic characteristics and illne…

Malemedicine.medical_specialtyPersonality InventoryDepression scaleSildenafilmedia_common.quotation_subjectPiperazinesSildenafil Citratechemistry.chemical_compoundErectile DysfunctionInternal medicinemedicineHumansIn patientSulfonesRisk factorDepression (differential diagnoses)Agedmedia_commonSelection biasDepressionMiddle Agedmedicine.diseasePsychiatry and Mental healthClinical PsychologyCross-Sectional StudiesTreatment OutcomeErectile dysfunctionchemistryPurinesPsychologyAfter treatmentClinical psychologyJournal of Affective Disorders
researchProduct

Relaxant effect of sildenafil in the rabbit basilar artery

2005

We hypothesized that sildenafil, inhibitor of phosphodiesterase-5 (PDE-5), interacts with the nitric oxide (NO)-cGMP pathway in the cerebral arteries and shows vasoactive effects. To prove it in the isolated rabbit basilar artery, we compared the effects of sildenafil with other PDE-5 inhibitors, assessed the endothelial dependence of the vasoactive responses, and used modulators of the cGMP and cAMP signaling processes. Sildenafil (10 nM-0.1 mM) induced concentration-dependent relaxations of endothelin-1 (10 nM)-precontracted basilar artery, which were partially inhibited both in endothelium-denuded arteries and in arteries precontracted by depolarization with KCl (50 mM). Endothelin-1 (1 …

Malemedicine.medical_specialtyPhosphodiesterase InhibitorsPhysiologySildenafilVasodilator AgentsCerebral arteriesVasodilationIn Vitro TechniquesPiperazinesSildenafil Citratechemistry.chemical_compound3'5'-Cyclic-GMP PhosphodiesterasesQuinoxalinesmedicine.arteryInternal medicinemedicineBasilar arteryAnimalsSulfonesCyclic Nucleotide Phosphodiesterases Type 5PharmacologyOxadiazolesDose-Response Relationship DrugPhosphoric Diester HydrolasesPDE5 drug designVasodilationNG-Nitroarginine Methyl EsterEndocrinologychemistryGuanylate CyclasePurinesBasilar Arterycardiovascular systemMolecular MedicineRabbitsSodium nitroprussideNitric Oxide SynthaseSoluble guanylyl cyclaseZaprinastSignal Transductionmedicine.drugVascular Pharmacology
researchProduct

Quality of partnership in patients with erectile dysfunction after sildenafil treatment.

2001

OBJECTIVE A comprehensive investigation on the quality of partnership of male patients with erectile dysfunction (ED) after treatment with sildenafil vs. untreated patients, as perceived by both the patients and their female partners. METHODS This report describes an observational, cross-sectional exploratory study comparing ED patients responsive to sildenafil with ED patients prior to therapy. Assessments included the 'International Index of Erectile Function' (IIEF) and the 'Partnerschaftsfragebogen' (PFB), a partnership questionnaire used in German-speaking countries. The comparability of the two study groups was examined using a stepwise logit model. Significant intergroup differences …

Malemedicine.medical_specialtySildenafilPhosphodiesterase InhibitorsLogistic regressionPiperazinesSildenafil Citratechemistry.chemical_compoundQuality of lifeErectile DysfunctionInternal medicineSurveys and QuestionnairesmedicineHumansPharmacology (medical)SulfonesMarriageGynecologybusiness.industryConfoundingGeneral MedicineMiddle Agedmedicine.diseaseTendernessPsychiatry and Mental healthSexual intercourseErectile dysfunctionCross-Sectional StudieschemistryPurinesObservational studyFemalemedicine.symptombusinessPharmacopsychiatry
researchProduct

DD-008 Monitoring of the adherence to therapies for the treatment of pulmonary hypertension

2015

Background Adherence to the treatment for pulmonary arterial hypertension (PAH) is an important aspect of chronic disease management to improve the efficacy of treatment. 1 Purpose The study aimed to evaluate adherence to long-term drug treatments for PAH. Material and methods From 01/01/2010 to 04/01/2014 a retrospective analysis was done on therapeutic plans and prescriptions related to patients in treatment for at least one year by the Pneumology Unit. Items dispensed by the Clinical Pharmacist were analysed through data entered into the database F file. Mean therapeutic adherence, according to the literature, 2 was calculated using the "pharmacy-refill" method: days of dispensed treatme…

Pediatricsmedicine.medical_specialtyAmbrisentanSildenafilbusiness.industrymedicine.diseasePulmonary hypertensionBosentanClinical pharmacychemistry.chemical_compoundTherapeutic AdherenceAcquired immunodeficiency syndrome (AIDS)chemistrymedicineGeneral Pharmacology Toxicology and PharmaceuticsMedical prescriptionbusinessmedicine.drugEuropean Journal of Hospital Pharmacy
researchProduct

Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.

2011

Endothelin receptor antagonists are used to treat idiopathic pulmonary arterial hypertension (IPAH), but human pulmonary arterial endothelin receptor expression is not well defined. We hypothesised that disease and treatment would modify normal receptor distribution in pulmonary resistance arteries of children. Using immunohistochemistry and semiquantitative analysis, we investigated endothelin receptor subtypes A and B (ET(A) and ET(B), respectively), and endothelial nitric oxide synthase (eNOS) expression in peripheral pulmonary arteries of tissue from untreated children with IPAH (n=7), following extended combined bosentan and epoprostenol therapy (n=5) and from normal subjects (n=5). Cl…

Pulmonary and Respiratory MedicineMalePathologymedicine.medical_specialtyEndotheliumAdolescentNifedipineNitric Oxide Synthase Type IIIEndothelin A Receptor AntagonistsEndothelin B Receptor AntagonistsHypertension PulmonaryVasodilator AgentsPulmonary ArteryMuscle Smooth VascularPiperazinesSildenafil CitrateNitric oxidechemistry.chemical_compoundEnosInternal medicinemedicineHumansFamilial Primary Pulmonary HypertensionSulfonesReceptorChildAntihypertensive AgentsSulfonamidesbiologybusiness.industryBosentanbiology.organism_classificationReceptor Endothelin AEpoprostenolReceptor Endothelin BEndothelin A Receptor AntagonistsBosentanEndothelin B Receptor Antagonistsmedicine.anatomical_structureEndocrinologychemistryPurinesChild PreschoolDrug Therapy CombinationFemaleEndothelium VascularEndothelin receptorbusinessmedicine.drugThe European respiratory journal
researchProduct

Relaxation induced by cGMP phosphodiesterase inhibitors sildenafil and zaprinast in human vessels

2000

Abstract Background . Sildenafil is currently used in the treatment of erectile dysfunction. However, assessment of direct effects of sildenafil on coronary arteries and on arteries used as coronary grafts is unknown. This study was designed to investigate the effects of sildenafil on contracted human coronary, internal mammary, and radial arteries obtained from multiorgan donors. The observations were extended to forearm veins. Zaprinast was included in this study for comparison. Methods . Segments of left coronary, internal mammary, and radial arteries, and forearm veins were obtained from 16 multiorgan donors. Vascular rings were suspended in organ bath chambers and isometric tension was…

Pulmonary and Respiratory Medicinemedicine.medical_specialtyPurinonesPhosphodiesterase InhibitorsSildenafilMuscle Smooth VascularPiperazinesSildenafil CitrateVeinschemistry.chemical_compound3'5'-Cyclic-GMP Phosphodiesterasesmedicine.arteryInternal medicinemedicineHumansSulfonesMammary ArteriesRadial arteryVeinDose-Response Relationship Drugbusiness.industryPhosphodiesteraseCoronary VesselsPDE5 drug designrespiratory tract diseasesVasodilationCoronary arteriesmedicine.anatomical_structurechemistryPurinesAnesthesiaRadial Arterycardiovascular systemCardiologySurgerySodium nitroprussideCardiology and Cardiovascular MedicinebusinessZaprinastmedicine.drugThe Annals of Thoracic Surgery
researchProduct

OP09.10: Hemodynamic effects of sildenafil administration in an animal model of preeclampsia

2011

Radiological and Ultrasound Technologybusiness.industrySildenafilObstetrics and GynecologyGeneral Medicinemedicine.diseasePreeclampsiachemistry.chemical_compoundAnimal modelReproductive MedicinechemistryAnesthesiaMedicineRadiology Nuclear Medicine and imagingbusinessAdministration (government)Hemodynamic effectsUltrasound in Obstetrics & Gynecology
researchProduct

UTILIZZO DEL SILDENAFIL CITRATO NELLA PREVENZIONE DEI CORPI CAVERNOSI NELLA IPP E NELL' INVECCHIAMENTO

2011

SILDENAFILCORPI CAVERNOSICITRATOINVECCHIAMENTOSettore MED/24 - Urologia
researchProduct